Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 727

1.

Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression.

Gantenbein N, Bernhart E, Anders I, Golob-Schwarzl N, Krassnig S, Wodlej C, Brcic L, Lindenmann J, Fink-Neuboeck N, Gollowitsch F, Stacher-Priehse E, Asslaber M, Gogg-Kamerer M, Rolff J, Hoffmann J, Silvestri A, Regenbrecht C, Reinhard C, Pehserl AM, Pichler M, Sokolova O, Naumann M, Mitterer V, Pertschy B, Bergler H, Popper H, Sattler W, Haybaeck J.

Eur J Cancer. 2018 Sep;101:165-180. doi: 10.1016/j.ejca.2018.07.001. Epub 2018 Aug 1.

2.

Bulk tumour cell migration in lung carcinomas might be more common than epithelial-mesenchymal transition and be differently regulated.

Zacharias M, Brcic L, Eidenhammer S, Popper H.

BMC Cancer. 2018 Jul 6;18(1):717. doi: 10.1186/s12885-018-4640-y.

3.

Afatinib restrains K-RAS-driven lung tumorigenesis.

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi: 10.1126/scitranslmed.aao2301.

PMID:
29925635
4.

Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung.

Brcic L, Stanzer S, Krenbek D, Gruber-Moesenbacher U, Absenger G, Quehenberger F, Valipour A, Lindenmann J, Stoeger H, Al Effah M, Fediuk M, Balic M, Popper HH.

Virchows Arch. 2018 Apr;472(4):589-598. doi: 10.1007/s00428-018-2326-0. Epub 2018 Mar 8.

5.

AKT3 drives adenoid cystic carcinoma development in salivary glands.

Zboray K, Mohrherr J, Stiedl P, Pranz K, Wandruszka L, Grabner B, Eferl R, Moriggl R, Stoiber D, Sakamoto K, Wagner KU, Popper H, Casanova E, Moll HP.

Cancer Med. 2018 Feb;7(2):445-453. doi: 10.1002/cam4.1293. Epub 2017 Dec 28.

6.

RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer.

Rao S, Sigl V, Wimmer RA, Novatchkova M, Jais A, Wagner G, Handschuh S, Uribesalgo I, Hagelkruys A, Kozieradzki I, Tortola L, Nitsch R, Cronin SJ, Orthofer M, Branstetter D, Canon J, Rossi J, D'Arcangelo M, Botling J, Micke P, Fleur L, Edlund K, Bergqvist M, Ekman S, Lendl T, Popper H, Takayanagi H, Kenner L, Hirsch FR, Dougall W, Penninger JM.

Genes Dev. 2017 Oct 15;31(20):2099-2112. doi: 10.1101/gad.304162.117. Epub 2017 Nov 8.

7.

Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition.

Tiran V, Lindenmann J, Brcic L, Heitzer E, Stanzer S, Tabrizi-Wizsy NG, Stacher E, Stoeger H, Popper HH, Balic M, Dandachi N.

Sci Rep. 2017 Aug 30;7(1):10040. doi: 10.1038/s41598-017-09929-0.

8.

Rebuttal from Professor Helmut H. Popper.

Popper HH.

Transl Lung Cancer Res. 2017 Apr;6(2):243-245. doi: 10.21037/tlcr.2017.04.08. No abstract available.

9.

Cons: the confusing mucinous adenocarcinoma classification.

Popper HH.

Transl Lung Cancer Res. 2017 Apr;6(2):234-240. doi: 10.21037/tlcr.2017.04.09. No abstract available.

10.

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Mairinger FD, Vollbrecht C, Flom E, Christoph DC, Schmid KW, Kollmeier J, Popper HH, Mairinger T, Walter RFH.

Oncotarget. 2017 Jun 6;8(23):37502-37510. doi: 10.18632/oncotarget.16398.

11.

[Interstitial processes of the lungs in childhood].

Popper H.

Pathologe. 2017 Jul;38(4):260-271. doi: 10.1007/s00292-017-0280-2. Review. German.

PMID:
28349192
12.

Signal Transducer and Activator of Transcription 1 (STAT1) Knock-down Induces Apoptosis in Malignant Pleural Mesothelioma.

Arzt L, Halbwedl I, Gogg-Kamerer M, Popper HH.

Pathol Oncol Res. 2017 Jul;23(3):595-605. doi: 10.1007/s12253-016-0157-3. Epub 2016 Dec 16.

PMID:
27987139
13.

Commentary on tumor heterogeneity.

Popper HH.

Transl Lung Cancer Res. 2016 Aug;5(4):433-5. doi: 10.21037/tlcr.2016.08.07. No abstract available.

14.

Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG).

Geltner C, Errhalt P, Baumgartner B, Ambrosch G, Machan B, Eckmayr J, Klikovits T, Hoda MA, Popper H, Klepetko W; Austrian Mesothelioma Interest Group (AMIG).

Wien Klin Wochenschr. 2016 Sep;128(17-18):611-7. doi: 10.1007/s00508-016-1080-z. Epub 2016 Sep 12.

15.

Pathology of Asbestosis: An Update of the Diagnostic Criteria Response to a Critique.

Roggli V, Gibbs AR, Attanoos R, Churg A, Popper H, Corrin B, Franks T, Galateau-Salle F, Galvin J, Hasleton P, Honma K.

Arch Pathol Lab Med. 2016 Sep;140(9):950-2. doi: 10.5858/arpa.2015-0503-SA. No abstract available.

PMID:
27575267
16.

Pathologists and liquid biopsies: to be or not to be?

Hofman P, Popper HH.

Virchows Arch. 2016 Dec;469(6):601-609. Epub 2016 Aug 23. Review.

PMID:
27553354
17.

[Neuroendocrine neoplasms of the mediastinum].

Brcic L, Heidinger M, Popper H.

Pathologe. 2016 Sep;37(5):434-40. doi: 10.1007/s00292-016-0198-0. Review. German.

PMID:
27507161
18.

RANKL/RANK control Brca1 mutation- .

Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, Kozieradzki I, Schramek D, Edokobi N, Hersl J, Sampson A, Odai-Afotey A, Lazaro C, Gonzalez-Suarez E, Pujana MA, Cimba F, Heyn H, Vidal E, Cruickshank J, Berman H, Sarao R, Ticevic M, Uribesalgo I, Tortola L, Rao S, Tan Y, Pfeiler G, Lee EY, Bago-Horvath Z, Kenner L, Popper H, Singer C, Khokha R, Jones LP, Penninger JM.

Cell Res. 2016 Jul;26(7):761-74. doi: 10.1038/cr.2016.69. Epub 2016 May 31.

19.

Loss of adipose triglyceride lipase is associated with human cancer and induces mouse pulmonary neoplasia.

Al-Zoughbi W, Pichler M, Gorkiewicz G, Guertl-Lackner B, Haybaeck J, Jahn SW, Lackner C, Liegl-Atzwanger B, Popper H, Schauer S, Nusshold E, Kindt AS, Trajanoski Z, Speicher MR, Haemmerle G, Zimmermann R, Zechner R, Vesely PW, Hoefler G.

Oncotarget. 2016 Jun 7;7(23):33832-40. doi: 10.18632/oncotarget.9418.

20.

Progression and metastasis of lung cancer.

Popper HH.

Cancer Metastasis Rev. 2016 Mar;35(1):75-91. doi: 10.1007/s10555-016-9618-0. Review.

21.

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.

Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, Pirker R, Douillard JY, Le Chevalier T, Filipits M, Rosell R, Kratzke R, Popper H, Soria JC, Shepherd FA, Seymour L, Tsao MS.

J Clin Oncol. 2016 Apr 10;34(11):1223-30. doi: 10.1200/JCO.2015.63.0970. Epub 2016 Feb 1.

22.

Clinical Manifestations of Respiratory Bronchiolitis as an Incidental Finding in Surgical Lung Biopsies: A Retrospective Analysis of a Large Austrian Registry.

Scheidl SJ, Kusej M, Flick H, Stacher E, Matzi V, Kovacs G, Popper HH, Costabel U, Olschewski H.

Respiration. 2016;91(1):26-33. doi: 10.1159/000442053. Epub 2015 Dec 12.

23.

Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival.

Geles A, Gruber-Moesenbacher U, Quehenberger F, Manzl C, Al Effah M, Grygar E, Juettner-Smolle F, Popper HH.

Virchows Arch. 2015 Dec;467(6):675-686. Epub 2015 Oct 8.

PMID:
26450556
24.

Old dilemma: asthma with irreversible airway obstruction or COPD.

Fattahi F, Vonk JM, Bulkmans N, Fleischeuer R, Gouw A, Grünberg K, Mauad T, Popper H, Felipe-Silva A, Vrugt B, Wright JL, Yang HM, Kocks JW, Hylkema MN, Postma DS, Timens W, Ten Hacken NH.

Virchows Arch. 2015 Nov;467(5):583-93. doi: 10.1007/s00428-015-1824-6. Epub 2015 Sep 14.

25.

Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study.

Ramlau R, Cufer T, Berzinec P, Dziadziuszko R, Olszewski W, Popper H, Bajcic P, Dusšk L, Zbozinkova Z, Pirker R; INSIGHT study team.

J Thorac Oncol. 2015 Sep;10(9):1370-1374. doi: 10.1097/JTO.0000000000000621.

26.

[Pulmonary Langerhans cell histiocytosis].

Popper HH.

Pathologe. 2015 Sep;36(5):451-7. doi: 10.1007/s00292-015-0052-9. Review. German.

PMID:
26289803
27.

Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study).

Hilbe W, Pall G, Kocher F, Pircher A, Zabernigg A, Schmid T, Schumacher M, Jamnig H, Fiegl M, Gächter A, Freund M, Kendler D, Manzl C, Zelger B, Popper H, Wöll E.

PLoS One. 2015 May 28;10(5):e0125364. doi: 10.1371/journal.pone.0125364. eCollection 2015.

28.

Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.

Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.

J Pathol. 2015 Oct;237(2):203-14. doi: 10.1002/path.4567. Epub 2015 Jul 14.

PMID:
26011651
29.

Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.

Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, Kratzke R, Graziano SL, Popper HH, Rosell R, Douillard JY, Le-Chevalier T, Pignon JP, Soria JC, Brambilla EM.

J Clin Oncol. 2015 Oct 20;33(30):3439-46. doi: 10.1200/JCO.2014.58.8335. Epub 2015 Apr 27.

30.

Minimal requirements for the molecular testing of lung cancer.

Popper HH, Tímár J, Ryska A, Olszewski W.

Transl Lung Cancer Res. 2014 Oct;3(5):301-4. doi: 10.3978/j.issn.2218-6751.2014.10.02. Review.

31.

Molecular testing in lung cancer in the era of precision medicine.

Popper HH, Ryska A, Tímár J, Olszewski W.

Transl Lung Cancer Res. 2014 Oct;3(5):291-300. doi: 10.3978/j.issn.2218-6751.2014.10.01. Review.

32.

Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.

Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, Bauer E, Blaas L, Hruschka N, Zboray K, Stiedl P, Nivarthi H, Bogner E, Gruber W, Mohr T, Zwick RH, Kenner L, Poli V, Aberger F, Stoiber D, Egger G, Esterbauer H, Zuber J, Moriggl R, Eferl R, Győrffy B, Penninger JM, Popper H, Casanova E.

Nat Commun. 2015 Mar 3;6:6285. doi: 10.1038/ncomms7285.

33.

Severe primary pulmonary lymphangiectasis in a premature infant: management and follow up to early childhood.

Reiterer F, Grossauer K, Pfleger A, Häusler M, Resch B, Eber E, Popper H, Urlesberger B.

Pediatr Int. 2015;57(1):166-9. doi: 10.1111/ped.12416.

PMID:
25711257
34.

Lung adenocarcinomas: comparison between mice and men.

Popper HH.

Methods Mol Biol. 2015;1267:19-43. doi: 10.1007/978-1-4939-2297-0_2.

PMID:
25636463
35.

Molecular diagnosis in lung diseases.

Calabrese F, Lunardi F, Popper H.

Front Biosci (Landmark Ed). 2015 Jan 1;20:644-88. Review.

PMID:
25553471
36.

The Th17 pathway in the peripheral lung microenvironment interacts with expression of collagen V in the late state of experimental pulmonary fibrosis.

Fabro AT, da Silva PH, Zocolaro WS, de Almeida MS, Rangel MP, de Oliveira CC, Minatel IO, Prando ED, Rainho CA, Teodoro WR, Velosa AP, Saber AM, Parra-Cuentas ER, Popper HH, Capelozzi VL.

Immunobiology. 2015 Jan;220(1):124-35. doi: 10.1016/j.imbio.2014.08.011. Epub 2014 Aug 18.

PMID:
25172545
37.

Usual interstitial pneumonia and smoking-related interstitial fibrosis display epithelial to mesenchymal transition in fibroblastic foci.

Fabro AT, Minatel IO, Rangel MP, Halbwedl I, Parra ER, Capelozzi VL, Popper H.

Respir Med. 2014 Sep;108(9):1377-86. doi: 10.1016/j.rmed.2014.06.008. Epub 2014 Jul 17.

38.

Signal transducer and activator of transcription 1 (STAT1) acts like an oncogene in malignant pleural mesothelioma.

Arzt L, Kothmaier H, Halbwedl I, Quehenberger F, Popper HH.

Virchows Arch. 2014 Jul;465(1):79-88. doi: 10.1007/s00428-014-1584-8. Epub 2014 May 17.

PMID:
24838635
39.

Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.

Pircher A, Gamerith G, Amann A, Reinold S, Popper H, Gächter A, Pall G, Wöll E, Jamnig H, Gastl G, Wolf AM, Hilbe W, Wolf D.

Lung Cancer. 2014 Jul;85(1):81-7. doi: 10.1016/j.lungcan.2014.04.001. Epub 2014 Apr 13.

PMID:
24780112
40.

Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.

Ma X, Rousseau V, Sun H, Lantuejoul S, Filipits M, Pirker R, Popper H, Mendiboure J, Vataire AL, Le Chevalier T, Soria JC, Brambilla E, Dunant A, Hainaut P; IALT-Bio working group.

Mol Oncol. 2014 May;8(3):555-64. doi: 10.1016/j.molonc.2013.12.015. Epub 2014 Jan 15.

41.

Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model - role of tumor stroma cells.

Leithner K, Wohlkoenig C, Stacher E, Lindenmann J, Hofmann NA, Gallé B, Guelly C, Quehenberger F, Stiegler P, Smolle-Jüttner FM, Philipsen S, Popper HH, Hrzenjak A, Olschewski A, Olschewski H.

BMC Cancer. 2014 Jan 25;14:40. doi: 10.1186/1471-2407-14-40.

42.

A dual role for autophagy in a murine model of lung cancer.

Rao S, Tortola L, Perlot T, Wirnsberger G, Novatchkova M, Nitsch R, Sykacek P, Frank L, Schramek D, Komnenovic V, Sigl V, Aumayr K, Schmauss G, Fellner N, Handschuh S, Glösmann M, Pasierbek P, Schlederer M, Resch GP, Ma Y, Yang H, Popper H, Kenner L, Kroemer G, Penninger JM.

Nat Commun. 2014;5:3056. doi: 10.1038/ncomms4056.

PMID:
24445999
43.

Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.

Pircher A, Manzl C, Fiegl M, Popper H, Pirker R, Hilbe W.

Lung Cancer. 2014 Mar;83(3):408-10. doi: 10.1016/j.lungcan.2013.12.007. Epub 2013 Dec 25.

PMID:
24412619
44.

EGFR autophosphorylation but not protein score correlates with histologic and molecular subtypes in lung adenocarcinoma.

Moldvay J, Barbai T, Bogos K, Piurko V, Fillinger J, Popper HH, Tímár J.

Diagn Mol Pathol. 2013 Dec;22(4):204-9. doi: 10.1097/PDM.0b013e3182936957.

PMID:
24193009
45.

BAP1 protein is a progression factor in malignant pleural mesothelioma.

Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH.

Pathol Oncol Res. 2014 Jan;20(1):145-51. doi: 10.1007/s12253-013-9677-2. Epub 2013 Aug 22.

PMID:
23963927
46.

Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA.

Graziano SL, Lacas B, Vollmer R, Kratzke R, Popper H, Filipits M, Seymour L, Shepherd FA, Rosell R, Veillard AS, Taron M, Pignon JP.

Lung Cancer. 2013 Oct;82(1):149-55. doi: 10.1016/j.lungcan.2013.06.015. Epub 2013 Aug 4.

47.

The issue of studies evaluating biomarkers which predict outcome after pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Mairinger F, Vollbrecht C, Mairinger T, Popper H.

J Thorac Oncol. 2013 Aug;8(8):e80-2. doi: 10.1097/JTO.0b013e31829b1cf9. No abstract available.

48.

Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.

Mairinger F, Vollbrecht C, Halbwedl I, Hatz M, Stacher E, Gülly C, Quehenberger F, Stephan-Falkenau S, Kollmeier J, Roth A, Mairinger T, Popper H.

J Thorac Oncol. 2013 May;8(5):644-53. doi: 10.1097/JTO.0b013e318287c224.

49.

PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.

Olaussen KA, Adam J, Vanhecke E, Vielh P, Pirker R, Friboulet L, Popper H, Robin A, Commo F, Thomale J, Kayitalire L, Filipits M, Le Chevalier T, André F, Brambilla E, Soria JC.

Lung Cancer. 2013 May;80(2):216-22. doi: 10.1016/j.lungcan.2013.01.014. Epub 2013 Feb 12.

PMID:
23410825
50.

Interstitial lung diseases-can pathologists arrive at an etiology-based diagnosis? A critical update.

Popper HH.

Virchows Arch. 2013 Jan;462(1):1-26. doi: 10.1007/s00428-012-1305-0. Epub 2012 Dec 7. Review.

PMID:
23224047

Supplemental Content

Loading ...
Support Center